GLP-1, SGLT2 medications may lower stroke survivor’s risk of …
3 days ago · The SGLT2 medications canagliflozin, dapagliflozin, empagliflozin and ertugliflozin are approved by the FDA for the treatment of Type 2 diabetes. To analyze the impact of these two classes of medications, this study reviewed medical records for more than 7,000 adults who had clot-caused, or ischemic , strokes between January 2000 and June 2022.
GLP-1 and SGLT2 inhibitors show promise in ... - News-Medical.net
3 days ago · After an average follow-up of three years, the analysis found: Adults who were taking either a GLP-1 or an SGLT2 had a 74% lower risk of death and an 84% lower risk of having a heart attack ...
GLP-1 and SGLT2 Drugs May Help Prevent Second Strokes and …
3 days ago · In a preliminary study set to be presented at the American Heart Association’s Scientific Sessions 2024, a team of researchers from the Mayo Clinic in Rochester, Minnesota, found that GLP-1 receptor agonists and SGLT2 inhibitors may significantly reduce the risk of heart attacks, second strokes, and death in adults who have previously had an ischemic stroke.
GLP-1RA Drugs, SGLT2 Inhibitors Prevent Liver Disease in T2D
2 days ago · Greater cumulative dosages of SGLT2 inhibitors were associated with a lower risk for NAFLD or NASH (OR, 0.61; 95% CI, 0.38-0.97). Study limitations include low number of GLP-1RA or SGLT2 inhibitor users, limited generalizability beyond ethnically Chinese individuals, and the prevalence of co-existing viral hepatitis among 5% of the study ...
Weight Loss Meds Help Stroke Survivors Prevent Stroke …
3 days ago · By Dennis Thompson HealthDay Reporter. MONDAY, Nov. 11, 2024 -- The weight-loss drug Ozempic can help reduce stroke patients’ risk of a heart attack or death, a new study says. GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes medications like Jardiance or Farxiga both helped protect the health of people following a stroke, researchers ...
GLP-1, SGLT2 medications may lower stroke sur | EurekAlert!
3 days ago · Adults who were taking either a GLP-1 or an SGLT2 had a 74% lower risk of death and an 84% lower risk of having a heart attack. Adults who were taking an SGLT2 were also at a 67% lower risk of ...
FDA Update: Sotagliflozin Approved For Broad HF Treatment
Jun 5, 2023 · The U.S. Food and Drug Administration (FDA) on May 26 approved a new drug application submitted by Lexicon Pharmaceuticals, Inc. for sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2 inhibitor for the treatment of heart failure (HF), including HF with preserved ejection fraction and HF with reduced ejection fraction.
FDA approves first SGLT1/SGLT2 inhibitor for heart failure
Jun 29, 2023 · Patients now have an even better chance at survival with the recent FDA approval of Inpefa, the brand name of the drug sotagliflozin. It is the first sodium glucose cotransporter (SGLT) inhibitor that addresses glucose reabsorption in both the kidneys and the small intestine.
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse ...
Apr 7, 2024 · Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Aug 27, 2021 · In patients with heart failure and a preserved ejection fraction, SGLT2 inhibition with empagliflozin led to a 21% lower relative risk in the composite of cardiovascular death or hospitalization...
- Some results have been removed